We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Concert Pharmaceuticals Initiates Phase 1b Clinical Trial of a Protease Inhibitor for Treatment of HIV
News

Concert Pharmaceuticals Initiates Phase 1b Clinical Trial of a Protease Inhibitor for Treatment of HIV

Concert Pharmaceuticals Initiates Phase 1b Clinical Trial of a Protease Inhibitor for Treatment of HIV
News

Concert Pharmaceuticals Initiates Phase 1b Clinical Trial of a Protease Inhibitor for Treatment of HIV

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Concert Pharmaceuticals Initiates Phase 1b Clinical Trial of a Protease Inhibitor for Treatment of HIV"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Concert Pharmaceuticals, Inc. announced that it has initiated a Phase 1b clinical study with CTP-518, its investigational oral HIV protease inhibitor for the treatment of HIV infection.

In connection with the start of this multiple ascending dose arm of the Phase 1 study, Concert will receive a $12 million milestone payment under the company’s strategic alliance with GlaxoSmithKline. The Phase 1b study will be used to assess the ability of CTP-518 to maintain acceptable therapeutic blood concentrations without a boosting agent such as ritonavir. It will also be used to determine doses for subsequent studies in HIV-infected patients.

“Preclinical data suggest that CTP-518 has the potential to be administered without pharmacokinetic boosting,” said Roger Tung, Ph.D., President and CEO of Concert Pharmaceuticals. “Ritonavir co-administration is currently recommended for all marketed HIV protease inhibitors. Our goal is to provide patients with a potent and well-tolerated once-daily therapy without the side effects, inconvenience and expense of an additional drug.”

The initial Phase 1 clinical trial is designed to evaluate the safety, tolerability and pharmacokinetics of CTP-518 in healthy volunteers after single and multiple doses. In addition, the Phase 1 study is intended to establish the pharmacokinetic enhancing effect of deuterium incorporation in CTP-518, and to determine whether CTP-518 dosed once-daily can maintain blood levels expected to be sufficient to suppress HIV replication when used as part of a standard three drug combination regimen.

The current standard of care is to co-administer all HIV protease inhibitors with ritonavir, except in patients who cannot tolerate ritonavir. The multiple ascending dose phase is a randomized, double-blind, placebo-controlled study in which study participants will receive CTP-518 or placebo for 14 days.

In June 2009, Concert and GlaxoSmithKline announced a potential $1 billion strategic alliance to develop three deuterium-containing medicines, including CTP-518. Concert has responsibility for research and development activities of CTP-518 through completion of Phase I studies. After the completion of the Phase I program, GSK may elect to obtain an exclusive, worldwide license to CTP-518. At such time, GSK would assume responsibility for development and commercialization.
Advertisement